VAM
PRQR icon

Visium Asset Management’s ProQR Therapeutics PRQR Stock Holding History

Visium Asset Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-275,000
Closed -$6.02M – 1261
2015
Q1 		$6.02M Buy
275,000
+25,000
+10% +$516K 0.09% 226
2014
Q4 		$5.42M Buy
250,000
+112,984
+82% +$1.71M 0.08% 241
2014
Q3 		$2.35M Buy
+137,016
New +$2.2M 0.03% 431

Other funds holding PRQR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Visium Asset Management's PRQR Position: Q2 2015 in Review

Visium Asset Management sold out of ProQR Therapeutics (PRQR) in Q2 2015, closing a stake of 275,000 shares — an estimated $6.02M sold.

Visium Asset Management first reported a position in PRQR in Q3 2014 and held it in 3 quarters. The position peaked at $6.02M in Q1 2015. 37 funds tracked by Wall St. Rank hold PRQR as of Q2 2015.

  • Visium Asset Management reported no remaining ProQR Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Visium Asset Management sold 275,000 ProQR Therapeutics shares in Q2 2015, an estimated $6.02M.
  • Visium Asset Management first reported a position in ProQR Therapeutics in Q3 2014 and held it in 3 quarters.
  • Visium Asset Management's ProQR Therapeutics position peaked at $6.02M in Q1 2015.
  • 37 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2015.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.